Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
about
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesNew molecularly targeted therapies for lung cancerGefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsmCurrent approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsEmerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling.Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma.Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.Targeted inhibition of kinases in cancer therapyPhosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancersExtreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancerThe prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis.Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variablesTargeted therapies for advanced Ewing sarcoma family of tumors.Akt inhibitors in clinical development for the treatment of cancer.Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinomaDiverse involvement of isoforms and gene aberrations of Akt in human lung carcinomas.Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancerHER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.TGF-beta inhibitors for the treatment of cancer.Pathogenesis of lung cancer: 100 year report.Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.Epidermal growth factor receptor inhibition and non-small cell lung cancer.Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.
P2860
Q24653036-EBE42A70-67C6-436D-A9CF-6207D90541B1Q24680988-D5871539-C63F-4564-B91D-3D194E02A081Q33265628-D66B9210-B4A9-40FB-8DFC-7BE76C6E5D3CQ33279462-50B4DB10-F94E-4B4B-9FA7-F3C090EA0E94Q33645556-4EEF14CF-0062-432D-AF1E-D29C2DA7E38DQ33857865-FE2D7333-9671-4229-AC37-6D2CBA91AA94Q33861210-321D98F2-E7D5-45C7-A9B2-4CC39AB20756Q33892582-EBD71807-A9E4-4631-9D60-EF5D5E331728Q33920097-1DC0C6A8-645B-4507-B60A-6E5C8E7A9A5AQ33990934-17BB4EEA-F655-4818-9F85-42E723E486B8Q34100976-223CB3D9-BEE3-4A46-AE09-A2B91A51C21BQ34557318-7C2AA830-E735-4031-8628-9637ADFD4267Q34582813-5B86ECBE-99E2-432A-B723-19D36B342A05Q34616626-ACF3F491-CD64-4A6D-9B3E-48F1A4ED12ABQ34683348-2D538782-8ED3-4444-8E97-9E975E67A5E5Q34970844-6CF8A0D3-35E3-4D2B-BF46-18C31C6A5581Q34989083-501E22A5-C47D-4533-9BEB-FD79E5CB3ABAQ35069595-62765A45-1900-4A72-BDC7-C3F54EC1DB4FQ35131931-6035D8B6-91FE-45F7-92B9-37FC9732A24CQ35589492-CECC5450-DD3E-4D00-A885-1925CBFB2348Q35628576-ED21B352-185A-43BD-BDBC-24D43D8E8E24Q35741627-E5E54C03-5ED9-4CDA-94AC-F0550EA29F45Q35754270-ECDFC3DF-37C2-456A-A521-05B2510FFC98Q35898597-7D76F736-CEF0-4575-9C7A-2D0B94DB7910Q36061145-0D281064-D75D-472C-A7F7-B5A25F3AEA7DQ36187040-94C23D19-407F-4DCB-9F94-1DD0DBE48916Q36233709-453C2885-E97B-446E-9319-C3A53EE90624Q36235591-D07F8D20-AD2A-44DC-BB90-73CFF718E756Q36249234-02BAEBE5-26E0-46A8-A838-E0FED91C44C3Q36293901-328E6B52-30F5-40B4-95B5-26E024DD13C9Q36414239-08847833-B43A-40EB-9298-3803A3510B09Q36504349-B2A254C2-A309-4AC3-90D4-A9503D813751Q36523502-BFEEADF5-A7A3-4FF8-AABB-41F9F97F5590Q36608839-FA305ECB-72B9-4303-9D4B-1DD6DCC7E5C8Q36610132-CE4F15B5-61C4-42BF-A32A-97868B2504B4Q36610166-8FD5E82D-C6D9-44AC-ACEC-19AF5A04F029Q36614353-2CA3A3B0-BE60-4F70-96ED-13F97064812CQ36615002-91CF3667-C077-4DB4-A24C-7CCE76AF70E5Q36691733-51830318-2F24-4AE4-90C6-5DAD312626C9Q36772562-F4C50E6F-52C1-4623-9786-C5DE7261EAE4
P2860
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Akt phosphorylation and gefiti ...... ed non-small-cell lung cancer.
@en
Akt phosphorylation and gefiti ...... ed non-small-cell lung cancer.
@nl
type
label
Akt phosphorylation and gefiti ...... ed non-small-cell lung cancer.
@en
Akt phosphorylation and gefiti ...... ed non-small-cell lung cancer.
@nl
prefLabel
Akt phosphorylation and gefiti ...... ed non-small-cell lung cancer.
@en
Akt phosphorylation and gefiti ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P356
P1476
Akt phosphorylation and gefiti ...... ed non-small-cell lung cancer.
@en
P2093
Alessandra Cancellieri
Anna Spreafico
Carlo Terenzio Paties
Cesare Calandri
Claudia Ligorio
Elisa Rossi
Elisabetta Magrini
Federico Cappuzzo
Giovanni Luca Ceresoli
Laura Lombardo
P2860
P304
P356
10.1093/JNCI/DJH217
P407
P577
2004-08-01T00:00:00Z